Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:27:31.575Z.
Calculation as of: 2026-10-06T20:27:31.575Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0b6e81bfb968b053e3c664bae947515aab5c23e1d2a9854177de48c3869b2902
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$4.83B
EBITDA Yield
N/A
TTM Avg
0.05%
3Y Avg
0.05%
5Y Avg
0.05%
Market Cap
$4.70B
EBITDA Yield
2.84%
TTM Avg
2.61%
3Y Avg
2.07%
5Y Avg
1.96%
Market Cap
$4.64B
EBITDA Yield
7.17%
TTM Avg
7.73%
3Y Avg
6.77%
5Y Avg
5.88%
Market Cap
$5.07B
EBITDA Yield
6.19%
TTM Avg
6.37%
3Y Avg
5.19%
5Y Avg
4.76%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | $4.84B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | N/A | 0.05% | 0.05% | 0.05% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.78B | N/A | N/A | N/A | N/A |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | N/A | N/A | N/A | N/A |
| Erasca, Inc. (ERAS)vs › | $4.96B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 2.84% | 2.61% | 2.07% | 1.96% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 7.17% | 7.73% | 6.77% | 5.88% |
| Waystar Holding Corp. (WAY)vs › | $5.06B | 6.62% | 6.48% | 5.36% | 5.36% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 6.19% | 6.37% | 5.19% | 4.76% |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 1.33% | 0.79% | 0.79% | 0.79% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
